HEAL-LAA Clinical Trial

Inclusion Criteria: * Subject is of legal age to participate in the study. * Subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve). * Subject is clinically indicated for and is treated or attempted to be treated with a WATCHMAN FLX™ Pro device. * Subject or legal representative is able to understand and willing to provide written informed consent to participate in the study. * Subject is able and willing to return for required follow-up visits and examinations. Exclusion Criteria: * Subject has a documented life expectancy of less than 6 months. * Subject is currently enrolled in another investigational study, except if the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatment. * Intracardiac thrombus is present. * An atrial septal defect repair or closure device or a patent foramen ovale repair or closure device is present. * The LAA anatomy will not accommodate a Closure Device. * The patient has known hypersensitivity to any portion of the device material or the individual components such that the use of the WATCHMAN FLX™ Pro Device is contraindicated. * Any of the customary contraindications for other percutaneous catheterization procedure (e.g., patient size too small to accommodate transesophageal echocardiography (TEE) probe or required catheters) or conditions (e.g., active infection…